Up-regulation of PPAR- Involved in the Therapeutic Effect of Icariin on Cigarette Smoke-Induced Inflammation

Qiuping Li,Hongying Zhang,Xinpeng Yan,Zhengxiao Zhao,Jian Qiu,Lingli Hu,Shan Jiang,Qing Kong,Jing Sun,Lulu Li
DOI: https://doi.org/10.1016/j.pupt.2023.102197
IF: 3.282
2023-01-01
Pulmonary Pharmacology & Therapeutics
Abstract:Icariin (ICA) might be a potential anti-inflammatory medication in a variety of diseases including COPD, and previous studies showed that ICA could attenuate cigarette smoke (CS)-induced inflammation by inhibiting nuclear factor (NF)-kappa B. Peroxisome proliferator-activated receptor (PPAR) gamma, a nuclear hormone receptor, has been reported to play a critical role in the inflammatory process in COPD. Whether PPAR-gamma is involved in the anti-inflammatory effect of icariin on COPD has scarcely been explored. This study aimed at investigating the role of ICA in PPAR-gamma expression in the CS-induced model, and then elucidating the therapeutic effects of ICA on COPD based on the PPAR gamma-NF-kappa B signaling pathway. The Beas-2B cells and H292 cells were induced with cigarette smoke extract (CSE) for 8 h after treatment with ICA for 16 h. The PPAR gamma expression and NF-kappa B pathway-related indicators were detected by western blotting, cellular immunofluorescence, and Real-time PCR. The PPAR gamma knock down or T0070907-treated Beas-2B cells were constructed to further investigate the rela-tionship between the inhibition of NF-kappa B by ICA and PPAR gamma. A COPD model was established by CS exposure for 6 months, and ICA (40 mg/kg) was administrated by gastric perfusion. Then, the pulmonary function, lung his-tology, inflammatory cytokine levels, and protein expressions were detected. We found ICA up-regulated PPAR gamma protein expression in both Beas-2B cells and H292 cells, and it improved CSE-induced PPAR gamma down regulation and NF-kappa B activation. Furthermore, the inhibition of NF-kappa B pathway by ICA was partially dependent on PPAR gamma in the PPAR gamma knock down or T0070907-treated Beas-2B cells, suggesting that ICA attenuated CSE-induced in-flammatory responses were associated with modulating the PPAR gamma-NF-kappa B pathway. Moreover, ICA showed similar effects on PPAR gamma and NF-kappa B expressions in the COPD model, and it effectively ameliorated the pulmonary function and lung inflammatory infiltration in the COPD rat model. Conclusively, the therapeutic effect of ICA on COPD was indirectly achieved by reducing airway inflammation, which was partially associated with modulating the PPAR gamma-NF-kappa B signaling pathway.
What problem does this paper attempt to address?